SYDNEY, Nov. 5, 2019 /PRNewswire/ -- AFT Pharmaceuticals is getting behind three charities in a bid to help them raise vital funding for vulnerable Aussies - and get people talking about health.
The company's founder and CEO, Hartley Atkinson says the initiative is an opportunity to give back to the community.
"My wife Marree and I started this company 20 years ago in a garage with a commitment to use innovation to make a real difference to people's health. Helping fund three of Australia's most important charities is a powerful way we can use our success to do good in the wider community."
The initiative sees AFT align itself with the Starlight Children's Foundation, Ovarian Cancer Research Foundation and Prostate Cancer Foundation of Australia.
Until 31st December 2019, AFT will donate A$1 of each Maxigesic® pack, purchased from any of the more than 2,300 participating Australian pharmacies, to the customer's choice of one of the three charities.
Hartley says, "Australians are known for looking after each other in times of hardship. This initiative gives our customers the opportunity to give back to their community by supporting worthy, health-based charities."
Every minute of every day, a child is admitted to hospital in Australia and every month children and their families make over 15,000 visits to Starlight Express Rooms. Starlight's mission is 'to brighten the lives of seriously ill and hospitalised children and young people'.
Nicola Tuck, partnerships executive at Starlight Children's Foundation, says the partnership will enable them to continue to brighten the hospital experience for children. "There is a return of A$5.70 value to the community for every A$1 invested in the Starlight Express Room program. A$39 helps brighten the hospital experience for 1 child, and A$30 gives a hospitalised teen access to a livewire creative workshop."
The Maxigesic® partnership will also support the Ovarian Cancer Research Foundation (OCRF). An estimated 1,500 new cases of ovarian cancer will be diagnosed in 2019, with the survival rate for all women diagnosed with ovarian cancer at 45 per cent.
"The extra funding will allow us to put more towards research projects aimed at early detection and personalised treatment. Survival rates improve dramatically when cancer is detected and treated early," says OCRF spokesperson Arbel Givargis.
"An important aim of the OCRF is to develop a test that is accurate, non-invasive and cost effective, so it becomes a habitual part of every women's regular health check-up routine, along with mammograms and pap smears."
Professor Jeff Dunn AO, CEO at Prostate Cancer Foundation of Australia commended the initiative saying, "The funds raised by Maxigesic® will help us save lives and support men with prostate cancer. Every year 1.3 million men worldwide are diagnosed with prostate cancer."
"Alarmingly, Australia has one of the highest incidence rates internationally, with 1 in every 7 Australian men likely to be diagnosed during their lifetime. This campaign will help us achieve research breakthroughs and provide much-needed support from Prostate Cancer Specialist Nurses around the country. We urge all Australians to get behind the campaign to help us beat prostate cancer."
The Prostate Cancer Foundation of Australia is the voice of 200,000 men living with prostate cancer. It promotes and funds world-leading research; offers support though groups and Prostate Cancer Specialist Nurses; and provides education programs for the Australian community and health professionals.
Maxigesic®, a world-first, specific-combination analgesic, was developed Down Under and is now licensed in more than 125 countries around the world.